EGON-ZEHNDER
14.11.2022 09:01:48 CET | Business Wire | Press release
Egon Zehnder, the world’s leadership advisory firm, today released the results of its 2022-2023 Global Board Diversity Tracker, revealing that while corporate boards are seeing steady progress on gender and racial and ethnic diversity, more action is needed on the broader goal of inclusivity which will improve the effectiveness of increasingly diverse boards.
Highlights from the Tracker include:
- The number of major companies with at least one woman on board has risen to 93 percent from 89 percent in 2020.
- Fastest progress over past 10 years is dominated by Western European countries, but Australasia, Canada, South Africa and Malaysia have transformed their boards too.
- In the U.S., 19 percent of directorships among Russell 3000 companies were held by non-white board members, up from 13 percent in 2019, according to data analyzed from Institutional Shareholder Services.
These increases in board diversity have illuminated a new need – for those organizations that have prioritized diverse representation to now develop an inclusive board culture that enables new perspectives to be shared and valued. As boards face increasing external pressure to modernize their operations, board chairs will play an important role as champions of inclusion and board effectiveness, while continuing to expand the definition of diversity.
While every seat on a board is highly impactful, further progress is needed in diversifying board leadership representation:
- In 2022, 25 percent of board committee leaders globally were women, up from 21.2 in 2020. There also was a slight increase in non-executive chair positions held by female directors to 8.4 percent, up from 7.2 percent in 2020, and to 3.7 percent in the number of female executive chair positions, a 0.7 percent increase from 2020.
- According to our analysis of Institutional Shareholder Services data, non-white directors in the Russell 3000 held 19 percent of directorships in 2022 and 9 percent of board chair roles. At the committee level, 13 percent of non-white directors were audit, compensation or nominating and governance committee chairs.
“We continue to see positive progress in diversifying boards, but we must recognize the hard work has only just begun and an increased focus on inclusion will ultimately drive meaningful progress. While every board’s journey will be different, the destination should look similar: a board with an inclusive culture with directors who bring a mix of experience that integrate unique perspectives into every decision the board makes,” said Pam Warren, co-leader of the Global Diversity, Equity & Inclusion Practice at Egon Zehnder. “To get there, it’s time to shift our attention to driving inclusivity by rethinking the process, culture, and operations that define the fabric of our boards. This will require vulnerability, learning and a commitment to change but the results will have deep impact for years to come.”
LGBTQ+ diversity also remains underrepresented and often undefined on boards. An Out Leadership report found that less than 1 percent of Fortune 500 companies have inclusive policies aimed at LGBTQ+ leaders, and only 26 out of 5,670 board seats are held by LGBTQ+ leaders—several of which are held by the same person. The report also found that only 41 Fortune 1000 companies define board diversity as inclusive of LGBTQ+ individuals.
Since the last Global Board Diversity Tracker two years ago, however, some progress happened: In 2021, Nasdaq enacted board diversity requirements for its roughly 3,000 listed companies to hire at least one woman as well as a racially diverse or LGBTQ+ individual, in addition to requiring disclosure of the demographic makeup of their board directors. In Canada, provisions have been put in place to increase female representation on boards to 50 percent and other minority groups (including members of the LGBTQ+ community) to 30 percent within five and seven years, respectively.
“It’s encouraging to see progress in the right direction, especially in countries such as Canada where there are provisions in place aimed at increasing women and minority representation, which includes LGBTQ+,” said Cynthia Soledad, co-leader of the Diversity, Equity & Inclusion Practice at Egon Zehnder. “As boards transition from focusing solely on representation to also considering inclusion, it will be crucial to evolve all board processes to be more inclusive, including meeting norms, director onboarding, and board leadership succession planning. The board chair will play a critical role in making this transition toward action.”
For additional data and action plan for inclusion within corporate boards, view the full Global Board Diversity Tracker report: https://www.egonzehnder.com/global-board-diversity-tracker.
About the Global Board Diversity Tracker
Released biennially over the last 18 years, the report tracks and analyzes global board diversity progress. This year’s report analyzed a total of 19,958 boards seats – using data from 1,776 publicly-traded companies across 44 countries with a combined market capitalization of €8bn – organizations that have the influence and opportunity to drive economic and culture impact for entire societies, as well as individuals. As every board’s journey will be different, Egon Zehnder included in the report additional sectors of diversity, offering case studies with directors, chief executives, and chairs globally to discuss the inclusion of ethnicity, sexual orientation, and other perspectives in the boardroom.
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory firm, inspiring leaders to navigate complex questions with human answers. We help organizations get to the heart of their leadership challenges and offer honest feedback and insights to help leaders realize their true being and purpose. Our 560 consultants across 63 offices and 37 countries are former industry and functional leaders who collaborate seamlessly across geographies, industries and functions to deliver the full power of the Firm to every client, every time.
We believe that together we can transform people, organizations and the world through leadership.
For more information, visit www.egonzehnder.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
